CENTRAL FAX CENTER JAN 1 5 2008

	^==	TIEIO A TE	05.540	SIMILE TRANSMISSI	ON LINDER	37 C F R 8	1.9			BRINK	
I hereby	section that this	an en anno a de	nee total	ing 4 pages including re	ched attachme	nts, is being	facsimile trans	emitte	d to	HOFE	
I hereby cartify that this correspondence, totalling 4 pages including recited attachments, is being facsimile transmitted to the United States Patent and Trademark Office at facsimile no.: 571-273-8300 (Central number) on the below date:								GILSO			
Date: January 15, 2008 Name: Janet L. Levoeka Signature: CMO to MULTURE								<u></u>	&LION		
		N THE	UNITE	D STATES PA	TENT AN	D TRẠD	EMARK	OF	FICE 1		
In re	Appln. of:										
Appin								Gembeh, Shirley			
Filed:	: February 13, 2004 Art Unit: 161							1614	,		
For:	METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE										
Attorr	ney Docke	t No:	1360	1-072							
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 TRANSMITTA								TAL			
Attach	ned is/are:										
\boxtimes	Power of Atl	iomey; St	atemen	t under 37 C.F.R. 3	.73(b); Assi	gnment.					
	Return Reco	eipt Postc	ard.							•	
Fee ca	alculation:										
	No additiona	al fee is re	quired.								
	Small Entity										
				nt of \$ for a _					37 C.F.R.	§ 1.136(a).	
	•	-		n an amount of \$			1.17(_).			
	An additiona	al tiling ter	e nas de	een calculated as sl	nown below			Τ			
	1		<u> </u>			Sme	II Entity		NotaS	mall Entity	
	Claims Re After Ame			Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	ог	Rate	Add'l Fee	
Total			Minus			x \$25=			x \$50=		
Indep.			Minus			x 100=			x \$200=		
First Pr	resentation of	Multiple De	p. Claim			+\$180=			+ \$360=		
						Total	\$		Total	\$	
Fee p	ayment:										
				is enclosed.							
	for this purp	ose.		ınt No. 23-1925 in 1			•	f this	Transmit	tal is enclose	
				amount of \$							
⊠	and any na	tent appli ee require	cation ped to e	rized to charge pay processing fees un nsure that this pay	der 37 CFF	₹ § 1.17 a	ssociated '	with	this pape	er (including	
					Respe	ctfully sub	mitted.		7		
lanun	ry 15, 2008				1	Man	KI	$igstyle \mathcal{L}$	40		
Date					Willa	n R. Boud	reaux (Reg	. No	35.796)		

Title

-

Director

BHGI

RECEIVED **CENTRAL FAX CENTER**

JAN 1 5 2008

PAGE 02/04

PTO/SB/80 (01-08) Approved for use through 12/31/2008, OMB 0651-0035 U.S. Petent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b) I hereby appoint: 00757 Practidoners associated with the Customer Number: Preclitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used): Registration Name Registration Number Number as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademerk Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b). Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to: 00757 The eddress associated with Customer Number: ORFirm or Individual Namo Address City State Country Email Telephone Assignee Name and Address: Hormos Medical Corporation Pharmacity, Itainen Pitkakatu 4 FIN-20520 Turku, Finland A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed. SIGNATURE of Assignse of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignee 07 Signature Telephone 734-913-9900 Name Zerbe Robert

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

JAN 1 5 2008 PTO/SB/96 (09-04)

Approved for use through 07/31/2008. OMB 0351-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3,73(b)						
Applicant/Patent Owner: Hormos Medical Corporation						
Application No./Patent No.: 10/777,211 Filed/Issue Date: February 1	3, 2004					
Entitled: METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE						
Hormos Medical Corporation . a <u>Corporation</u> (Name of Assignee) (Type of Assignoo, e.g., corporation)	tion, partnership, university, government agancy, atc.)					
states that it is: 1. the assignee of the entire right, title, and interest; or						
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%						
in the patent application/patent identified above by virtue of either:						
A assignment from the inventor(s) of the patent application/patent identifie in the United States Patent and Trademark Office at Reel, Future thereof is attached.	d above. The assignment was recorded ame, or for which a copy					
B. A chain of title from the inventor(s), of the patent application/patent identified below.	I above, to the current assignee as shown					
1. From: To: To: The document was recorded in the United States Patent and Tradem Reel, Frame, or for which a cop	ark Office at y thereof is attached.					
2 From: To:						
The document was recorded in the United States Patent and Tradem Reel, Frame, or for which a content of the Cont	ark Office at opy thereof is attached.					
From:	ark Office at					
Reel, Frame, or for which a	copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sho	eet					
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment documen Division in accordance with 37 CFR Part 3, if the assignment is to be recompted assignment in the chain of title are attached.	t(s)) must be submitted to Assignment orded in the records of the USPTO. <u>See</u>					
The undersigned (whose the is supplied below) is authorized to act on behalf of the						
Signature	January 15, 2008 Date					
William R. Boudreaux	734-302-6000					
Printed or Typed Name	Telephone Number					
Attorney for Hormos Medical Corporation						

This collection of information is required by 37 CFR 3,73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED

JAN 1 5 2008

ASSIGNMENT

WHEREAS, I, Markku ANTTILA, a citizen of Finland, residing at Pajulantie 2, FIN-20320, Turku, Finland (hereinafter collectively referred to as "Assignor") am the inventor of an invention in METHOD FOR ENHANCING THE BIOAVAILABITYOF OSPEMIFENE, for which I have executed an application for Letters Patent of the United States, scrial number 10/777,211, filed 13 February 2004; and

WHEREAS, HORMOS MEDICAL CORPORATION, incorporated in the country of Finland, with a place of business at Itäinen Pitkäkatu 4 B, FIN-20520 Turku, Finland (hereinafter referred to as "Assignee"), is desirous of obtaining the entire right, title and interest in, to and under the said invention and the said application;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) to us in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, I the said Assignor have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said Assignee, its successors, legal representatives and assigns, the entire right, title and interest in, to and under the said invention, and the said application and all divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may be granted for said invention in any country or countries foreign to the United States, and all Letters Patent which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all rights of priority in any such country or countries based upon the filing of the said application for Letters Patent of the United States which are created by any law, treaty or international convention; an I hereby authorize and request the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for said invention to the said Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND I HEREBY covenant that I have full right to convey the entire interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

AND I HEREBY further covenant and agree that I will communicate to said Assignce, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said Assignce, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said invention in all countries.

AND I HEREBY covenant that I have full right to convey the entire interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

AND I HEREBY further covenant and agree that I will communicate to said Assignce, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said invention in all countries.

IN TESTIMONY WHEREOF, I hereunto set our hands and scals the day and year set opposite our respective signatures.

Date	May	2Y 20	2004	Markku A		L.S
	4			D 62	XXXX	